Academia, industry and the slow adoption of new treatments - Top-Institutions - MDSpire

Academia, industry and the slow adoption of new treatments

  • By

  • Pavel Klein

  • Amanda Pong

  • Matthias Koepp

  • Wolfgang Löscher

  • Josemir W Sander

  • Edward Faught

  • August 12, 2025

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Translational Medicine
    • Clinical Research
    • Bioethics

  • #2

    Massachusetts General Hospital / Harvard Medical School
    Massachusetts General Hospital / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Clinical Trials
    • Pharmaceutical Collaboration
    • Health Policy

  • #3

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Pharmaceutical Sciences
    • Clinical Research
    • Regulatory Science

  • #4

    University of Pennsylvania
    University of Pennsylvania

    Philadelphia, PA

    Key Differentiators

    • Clinical Research
    • Bioethics
    • Pharmaceutical Collaboration

  • #5

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Clinical Trials
    • Pharmaceutical Collaboration
    • Health Policy

Original Source(s)

Academia, industry and the slow adoption of new treatments

  • by Pavel Klein, Amanda Pong, Matthias Koepp, Wolfgang Löscher, Josemir W Sander, Edward Faught

  • August 12, 2025

Related Content

A novel gain-of-function mutation (W818R) of calcium-sensing receptor in a family with autosomal dominant hypocalcemia type 1

Comprehensive Epilepsy Program marks 100th responsive neurostimulation procedure

UCI Health physicians have completed their 100th procedure using the RNS® System.

  • by

  • April 8, 2026

  • 1 min
SGLT2 Inhibitors Linked to Lower Epilepsy Risk

Real-world cohort data show lower epilepsy risk vs DPP-4 inhibitors in older patients with type 2 diabetes